190 related articles for article (PubMed ID: 37828105)
1. Exploration of a screening model for intrahepatic cholangiocarcinoma patients prone to cuproptosis and mechanisms of the susceptibility of CD274-knockdown intrahepatic cholangiocarcinoma cells to cuproptosis.
Shen Z; Cai J; Tao L; Zheng J; Ye Z; Liu Y; Pan H; Wang Y; Xu J; Liang X
Cancer Gene Ther; 2023 Dec; 30(12):1663-1678. PubMed ID: 37828105
[TBL] [Abstract][Full Text] [Related]
2. Identification of Novel Cuproptosis-Related Genes Mediating the Prognosis and Immune Microenvironment in Cholangiocarcinoma.
Liu Q; Zhu J; Huang Z; Zhang X; Yang J
Technol Cancer Res Treat; 2024; 23():15330338241239139. PubMed ID: 38613350
[TBL] [Abstract][Full Text] [Related]
3. Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic Cholangiocarcinoma.
Dong Z; Liao B; Shen W; Sui C; Yang J
Dig Dis Sci; 2020 Feb; 65(2):480-488. PubMed ID: 31410753
[TBL] [Abstract][Full Text] [Related]
4.
Wu J; Guo Y; Zuo ZF; Zhu ZW; Han L
World J Gastroenterol; 2023 May; 29(19):2961-2978. PubMed ID: 37274806
[TBL] [Abstract][Full Text] [Related]
5. A cuproptosis-related gene expression signature predicting clinical prognosis and immune responses in intrahepatic cholangiocarcinoma detected by single-cell RNA sequence analysis.
Ren H; Liu C; Zhang C; Wu H; Zhang J; Wang Z; Chen L; Wang H; Shao C; Zhou L
Cancer Cell Int; 2024 Mar; 24(1):92. PubMed ID: 38431620
[TBL] [Abstract][Full Text] [Related]
6. EMLI-ICC: an ensemble machine learning-based integration algorithm for metastasis prediction and risk stratification in intrahepatic cholangiocarcinoma.
Ruan J; Xu S; Chen R; Qu W; Li Q; Ye C; Wu W; Jiang Q; Yan F; Shen E; Chu Q; Jia Y; Zhang X; Fu W; Chen J; Timko MP; Zhao P; Fan L; Shen Y
Brief Bioinform; 2022 Nov; 23(6):. PubMed ID: 36259363
[TBL] [Abstract][Full Text] [Related]
7. LKB1 inhibits intrahepatic cholangiocarcinoma by repressing the transcriptional activity of the immune checkpoint PD-L1.
Liu Z; Li S; Zeng J; Zhou X; Li H; Liu X; Li F; Jiang B; Zhao M; Ma T
Life Sci; 2020 Sep; 257():118068. PubMed ID: 32653521
[TBL] [Abstract][Full Text] [Related]
8. Immune-related RNA signature predicts outcome of PD-1 inhibitor-combined GEMCIS therapy in advanced intrahepatic cholangiocarcinoma.
Zeng TM; Pan YF; Yuan ZG; Chen DS; Song YJ; Gao Y
Front Immunol; 2022; 13():943066. PubMed ID: 36159865
[TBL] [Abstract][Full Text] [Related]
9. Tumor-derived exosomes induce immunosuppressive macrophages to foster intrahepatic cholangiocarcinoma progression.
Luo C; Xin H; Zhou Z; Hu Z; Sun R; Yao N; Sun Q; Borjigin U; Wu X; Fan J; Huang X; Zhou S; Zhou J
Hepatology; 2022 Oct; 76(4):982-999. PubMed ID: 35106794
[TBL] [Abstract][Full Text] [Related]
10. YTHDF2 promotes intrahepatic cholangiocarcinoma progression and desensitises cisplatin treatment by increasing CDKN1B mRNA degradation.
Huang CS; Zhu YQ; Xu QC; Chen S; Huang Y; Zhao G; Ni X; Liu B; Zhao W; Yin XY
Clin Transl Med; 2022 Jun; 12(6):e848. PubMed ID: 35696608
[TBL] [Abstract][Full Text] [Related]
11. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma.
Guo XJ; Lu JC; Zeng HY; Zhou R; Sun QM; Yang GH; Pei YZ; Meng XL; Shen YH; Zhang PF; Cai JB; Huang PX; Ke AW; Shi YH; Zhou J; Fan J; Chen Y; Yang LX; Shi GM; Huang XY
Front Immunol; 2021; 12():705378. PubMed ID: 34526987
[TBL] [Abstract][Full Text] [Related]
12. The prognostic significance and therapeutic potential of hedgehog signaling in intrahepatic cholangiocellular carcinoma.
Tang L; Tan YX; Jiang BG; Pan YF; Li SX; Yang GZ; Wang M; Wang Q; Zhang J; Zhou WP; Dong LW; Wang HY
Clin Cancer Res; 2013 Apr; 19(8):2014-24. PubMed ID: 23493353
[TBL] [Abstract][Full Text] [Related]
13. Quercetin Inhibits Intrahepatic Cholangiocarcinoma by Inducing Ferroptosis and Inhibiting Invasion via the NF-[Formula: see text]B Pathway.
Song Y; Zhang Z; Chai Q; Zheng H; Qi Y; Xia G; Yu Z; Yang R; Huang J; Li Y; Peng C; Jiang B; Liu S
Am J Chin Med; 2023; 51(3):701-721. PubMed ID: 36823098
[TBL] [Abstract][Full Text] [Related]
14. PD-1 blockade and radiotherapy combination for advanced Epstein-Barr virus-associated intrahepatic cholangiocarcinoma: a case report and literature review.
Liao CX; Deng CS; Liang X; Yang JC; Chen ZZ; Lin XY; Lin CF; Chen S; Wu SS
Front Immunol; 2023; 14():1239168. PubMed ID: 37753076
[TBL] [Abstract][Full Text] [Related]
15. Bufalin targeting CAMKK2 inhibits the occurrence and development of intrahepatic cholangiocarcinoma through Wnt/β-catenin signal pathway.
Zhang H; Dong X; Ding X; Liu G; Yang F; Song Q; Sun H; Chen G; Li S; Li Y; Wang M; Guo T; Zhang Z; Li B; Yang L
J Transl Med; 2023 Dec; 21(1):900. PubMed ID: 38082327
[TBL] [Abstract][Full Text] [Related]
16. [Prediction of prognosis of patients with radical resection of intrahepatic cholangiocarcinoma based on single cell omics].
Chen JL; Tang Y; Qin DL; Li ZL; Tang ZH; Quan ZW
Zhonghua Wai Ke Za Zhi; 2024 Apr; 62(4):316-323. PubMed ID: 38432673
[No Abstract] [Full Text] [Related]
17. A metabolism-related 4-lncRNA prognostic signature and corresponding mechanisms in intrahepatic cholangiocarcinoma.
Zou W; Wang Z; Wang F; Li L; Liu R; Hu M
BMC Cancer; 2021 May; 21(1):608. PubMed ID: 34034689
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.
Huang YH; Zhang CZ; Huang QS; Yeong J; Wang F; Yang X; He YF; Zhang XL; Zhang H; Chen SL; Zheng YL; Deng R; Lin CS; Yang MM; Li Y; Jiang C; Kin-Wah Lee T; Ma S; Zeng MS; Yun JP
J Hepatol; 2021 Apr; 74(4):838-849. PubMed ID: 33212090
[TBL] [Abstract][Full Text] [Related]
19. Notch1 is overexpressed in human intrahepatic cholangiocarcinoma and is associated with its proliferation, invasiveness and sensitivity to 5-fluorouracil in vitro.
Wu WR; Zhang R; Shi XD; Zhu MS; Xu LB; Zeng H; Liu C
Oncol Rep; 2014 Jun; 31(6):2515-24. PubMed ID: 24700253
[TBL] [Abstract][Full Text] [Related]
20. Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis.
Chao J; Wang S; Wang H; Zhang N; Wang Y; Yang X; Zhu C; Ning C; Zhang X; Xue J; Zhang L; Piao M; Wang M; Yang X; Lu L; Zhao H
Cancer Immunol Immunother; 2023 Nov; 72(11):3717-3726. PubMed ID: 37787790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]